The human epidermal growth factor receptor-2 (HER-2)-enriched molecular subtype of breast cancer responds to HER-2 targeted and/or to endocrine therapy, depending on the presence of functional hormone receptors. These long-term therapeutic options are associated with systemic toxicity and acquired drug resistance. Resistance to conventional and targeted chemo-endocrine therapy leads to the emergence of drug-resistant cancer stem cells that promote therapy-resistant disease progression. Relatively non-toxic natural phytochemicals may provide testable alternatives to therapy-resistant breast cancer. The present review summarizes data on the following: i) Growth inhibitory efficacy of mechanistically distinct natural phytochemicals in a preclinical model for HER-2-enriched breast cancer; ii) drug-resistant stem cell model for HER-2-enriched breast cancer; and iii) proof of concept for efficacy of natural phytochemicals as testable alternatives against drug-resistant cancer stem cells. Relative to the non-tumorigenic human mammary epithelial 184-B5 cells, HER-2 expressing tumorigenic 184-B5/HER cells (HER-2-enriched breast cancer model) exhibit hyper-proliferation and increased anchorage independent colony formation. Resistance to lapatinib, a small molecule inhibitor of EGFR and HER-2, provides the LAP-R phenotype that exhibits increased tumor spheroid formation and an upregulated expression of the stem cell markers, CD44, NANOG and OCT-4. Select bioactive natural phytochemicals, such as cruciferous glucosinolate, tea polyphenol, soy isoflavone and rosemary terpenoid at their respective maximum cytostatic concentrations exert anti-proliferative and pro-apoptotic effects on parental 184-B5/HER cells and downregulate the phosphorylation of HER-2. The expression of stem cell markers in the LAP-R phenotype is effectively inhibited by a bioactive terpenoid. Collectively, these data validate an experimental approach to identify efficacious natural phytochemicals as testable therapeutic alternatives for chemo-endocrine therapy resistant breast cancer.
HER-2-enriched breast cancerdrug resistancestem cellsnatural phytochemicalsgrowth inhibitionapoptosis1. Introduction
Global gene expression profiling of clinical breast cancer has provided molecular classification of subtypes based of differential expression of genes for hormone and growth factor receptors (1). This molecular classification dictates specific conventional chemo-endocrine therapy or pathway selective small molecule inhibitor based targeted therapy. Thus, for the hormone receptor-positive/human epidermal growth factor receptor-2 (HER-2)-positive luminal B molecular subtype, treatment with selective estrogen receptor modulators, aromatase inhibitors and HER-2 inhibitors represent common options (2). By contrast, for the hormone receptor-negative/HER-2-positive HER-2 enriched subtype HER-2-targeted therapy represents a viable option (3).
Long-term treatment with conventional and/or targeted therapy is frequently associated with systemic toxicity and acquired tumor resistance that collectively compromise patient compliance and favor therapy-resistant tumor progression predominantly due to the emergence of drug-resistant cancer stem cells (4).
In preclinical investigations, human breast carcinoma-derived BT474, MDA-MB-361 and MCF-7/HER cell models for the luminal B subtype, and SKBr-3 and MDA-MB-435 cell models for the HER-2-enriched subtype (5,6), represent valuable experimental systems with which to elucidate the mechanisms of drug resistance and for the identification of efficacious lead compounds. Multiple drug resistance via acquired resistance to HER-2/EGFR-selective small molecule inhibitors in the HER-2-enriched model (3) or cross-resistance to aromatase inhibitors in the MCF-7AROM model (7,8) represent additional approaches. Recent advances in the development of human cancer models include genetically engineered mouse models and constituent cells lines, patient-derived xenografts and constituent organoid models, and drug-resistant cancer stem cell models. Collectively, these approaches promise the clinical translation of preclinical data.
Acquired drug resistance leads to the lack of a response to conventional and/or targeted chemo-endocrine therapy, and is frequently is associated with therapy-resistant cancer stem cells that are characterized by pluripotency, tumor-initiating potential and the upregulated expression of several cell surface proteins and nuclear transcriptional factors (9).
The limitations of chemo-endocrine and/or targeted therapy emphasize an unmet need to develop clinically relevant cancer stem cell models and identify efficacious testable alternatives for stem cell targeted therapy of chemo-endocrine therapy resistant breast cancer.
The present review summarizes a comparison of recently generated unpublished data with that from previously published data on the following: i) Growth inhibitory efficacy of mechanistically distinct natural phytochemicals on a cellular model for the HER-2-enriched breast cancer subtype; ii) drug-resistant stem cell model for HER-2-enriched breast cancer; and iii) proof of concept for efficacy of natural phytochemicals as testable alternatives for drug resistant breast cancer stem cells.
2. Cellular models
The human tissue-derived cellular models included in the present review are distinct from those established human breast carcinoma-derived cell lines as models for the HER-2-enriched breast cancer subtype. In the present 184-B5/HER model, non-tumorigenic human mammary epithelial cells (10) stably transfected with HER-2 oncogene exhibit tumorigenic transformation due to the overexpression of the HER-2 oncogene (11).
Cell lines in experimental models
The following cell lines represent the experimental models: i) 184-B5: This cell line was established from a histologically normal reduction mammoplasty sample. These cells lack the expression of ER, PR and HER-2 and are non-tumorigenic (10). These cells represent a baseline control for investigations on 184-B5/HER and Lapatinib resistant (LAP-R) models. ii) 184-B5/HER: This cell line over-expresses HER-2 oncogene. The cells are ER/PR negative and HER-2 positive, and produce tumors on in vivo transplantation (11). iii) 184-B5/HER (LAP-R): These cells are resistant to lapatinib, a small molecule inhibitor of EGFR and HER-2. These cells exhibit the downregulated expression of p-EGFR and p-HER-2, and the upregulated expression of several stem cell specific cellular and molecular markers (12).
Quantitative end point biomarkers
The quantitative parameters include population doubling times, saturation density, as monitored by viable cell number using trypan blue dye exclusion assay. Cell cycle progression and cellular apoptosis are monitored by flow cytometry and presented as the G1:S+G2/M ratio and the sub-G0 phase. The expression levels of select cell cycle regulatory and apoptosis-specific proteins are monitored by flow cytometry-based quantitative immunofluorescence assay that involves the sorting of cells positive for FITC-conjugated antibody (13). The fluorescence data are expressed as log mean fluorescent units (FU) per 104 fluorescent events following normalization by FU of cells stained with FITC-IgG antibody.
The statistically significant differences between the control and treatment groups were analyzed using a two sample Student's t-test, one-way ANOVA and Dunnett's post hoc multiple comparisons test with a threshold of α=0.05, and the Chi square test where appropriate.
3. Natural phytochemicals
These agents are selected based on their documented chemo-preventive efficacy in preclinical models of epithelial organ site cancers. To ascertain the feasibility of the experimental approach, select phytochemicals, such as cruciferous glucosinolate indole-3-carbinol (I3C), tea polyphenol epigallocatechin gallate (EGCG), soy isoflavone genistein (GEN) and rosemary terpenoids carnosic acid (CA) and carnosol (CSOL), are tested on the non-tumorigenic 184-B5 cells. Subsequently these agents are tested for their growth inhibitory efficacy on the 184-B5/HER model. Compared to the 184-B5 model, the 184-B5/HER model exhibits substantially greater growth inhibitory efficacy. At the mechanistic levels, I3C alters the cellular metabolism of estradiol to generate the anti-proliferative metabolite 2-hydroxyestrone (14). EGCG and GEN inhibit the expression of proliferative cell nuclear antigen (PCNA) and cyclin D1, and increase the expression of the cyclin-dependent kinase inhibitor (CDKI) p16INK4 (15). CA and CSOL inhibit tyrosine kinase expression and upregulate p16INK4 expression (15), induce cytostatic G2/M arrest and accumulate G2-specific cyclin B1(16). CSOL also inhibits the expression of inducible cyclo-oxygenase-2 (COX-2) via the protein kinase C/mitogen-activated protein kinase (PKC/MAPK) pathway (17).
4. Status of hyper-proliferation
The data on the status of hyper-proliferation in 184-B5/HER model are summarized in Table I. In comparison with the non-tumorigenic 184-B5 cells, the hyper-proliferative 184-B5/HER cells exhibit an approximately 55% reduction in population doubling times, an approximately 63% increase in saturation density, an approximately 96% reduction in the sub-G0 (apoptotic) population and a substantial increase in anchorage-independent colony formation, the latter being an established in vitro surrogate end point for in vivo tumor development (16). In addition, the 184-B5/HER cells exhibit an approximately 178-fold increase in HER-2 expression and an approximately 231-fold increase in pHER-2 expression.
5. Growth inhibitory efficacy of natural phytochemicals
The data on the growth inhibitory efficacy of natural phytochemicals is summarized in Table II. Treatment with individual phytochemicals at their respective maximum cytostatic (IC90) concentrations resulted in a substantial increase in the G1:S+G2/M ratio ranging from approximately 43% for CA to approximately 3-fold for GEN. This increase in the G1:S+G2/M ratio is indicative of cytostatic growth arrest. At the mechanistic level, phytochemical treatment resulted in the downregulated expression of p-HER-2, ranging from approximately 20% for CA to approximately 85% for GEN. In addition, these data facilitate the rank ordering of natural phytochemicals based on their efficacy for biomarker modulation. Thus, with regard to the G1:S+G2/M ratio, the rank order is GEN>I3C>EGCG>CA=CSOL. For pHER-2 inhibition the rank order is GEN>EGCG>I3C>CSOL>CA. Thus, the rank order suggests distinct efficacy for p-HER-2 inhibition that may be responsible for the observed effect on cell cycle progression.
The data on the pro-apoptotic effects of the phytochemicals are summarized in Table III. Treatment with the phytochemicals results in a substantial increase of the cell population in the sub-G0 (apoptotic) phase of the cell cycle ranging from approximately 8-fold for I3C to approximately 17-fold for GEN, relative to the solvent control. At the mechanistic level, the induction of cellular apoptosis was associated with a reciprocal modulation of apoptotic-specific proteins due to the reduced expression of the anti-apoptotic BCL-2 protein, ranging from approximately 23% for I3C to approximately 67% for GEN, and the increased expression of pro-apoptotic BAX protein, ranging from approximately 23% for I3C to approximately 76% for CSOL (Table IV). Thus, with regard to the induction of apoptosis, the rank order is GEN>CSOL>EGCG>CA>I3C. The rank order for the decrease in BCL-2 expression is GEN>CSOL>CA>EGCG>I3C, while the rank order for the increase in BAX expression is CSOL>GEN>CA>EGCG>I3C. Collectively, the rank order for the efficacy for induction of cellular apoptosis indicates distinct mechanisms of action for individual phytochemical. It is also notable that the growth inhibitory effects of these phytochemicals have been reported in the HER-2-negative human breast carcinoma derived cell lines, MCF-7, MCF-10 CA 1a and MDA-MB-231 (18-21). However, the effective concentrations differ from the ones presented for the 184-B5/HER model.
6. Drug-resistant stem cell model
In the preclinical models for HER-2-enriched breast cancer, the HER-2-specific antibody, trastuzumab, and the HER-2/EGFR dual-specific small molecule inhibitors display acquired drug resistance (22,23). Consistent with these data, the 184-B5/HER cells treated with the HER-2/EGFR small molecule inhibitor, lapatinib (LAP), provided the drug-resistant stem cell model. Long-term treatment with the maximum cytostatic (IC90) concentration of LAP generated progressively growing LAP-R cells. The data summarized in Table V demonstrate an approximately 1-fold increase in the number of tumor spheroids, an approximately 3-fold increase in cluster of differentiation (CD44), a 3-fold increase in DNA binding homeobox nuclear transcription factor (NANOG) and a 2-fold increase in octamer binding transcription factor-4 (OCT-4), relative to that observed in LAP-sensitive (LAP-S) cells. The cell surface marker, CD44, and the nuclear transcription factors, NANOG and OCT-4, represent well-established markers of the stem cell population (9). Thus collectively, these data indicate that the LAP-R cells may represent putative cancer stem-like cells in the present model.
7. Stem cell targeting testable alternatives
Frequent occurrence of acquired tumor resistance against pharmacological therapeutic agents (2,3,7,8) and the emergence of drug-resistant cancer stem cells (22,23) emphasizes an unmet need to identify stem cell targeting testable alternatives. Unlike pharmacological agents, natural phytochemicals, due to their low toxicity profiles, are less likely to induce acquired tumor resistance. Published studies on the rosemary terpenoids, CA and CSOL, have documented potent anti-proliferative and/or pro-apoptotic effects at cytostatic low µM concentrations on the present HER-2-enriched model (16). It is therefore of considerable relevance to examine the stem cell targeted efficacy of natural phytochemicals. The data presented in Table VI demonstrate that in response to a treatment with CSOL the LAP-R cells exhibit an approximately 87% decrease in the number of tumor spheroids, an 86% decrease in CD44 expression, a 77% decrease in NANOG and an 80% decrease in OCT-4 expression, relative to the solvent-treated controls. Collectively, these data provide a proof of concept for a mechanistic lead for the rosemary terpenoid, CSOL, as a stem cell targeting natural alternative. With regard to the cancer stem cell-targeted efficacy of natural products, it is noteworthy that several mechanistically distinct natural products have documented efficacy against drug resistant stem cell population. For example, the vitamin A derivative, all-trans retinoic acid (ATRA), inhibits gastric cancer stem cell growth via inhibiting CD44, aldehyde dehydrogenase-1 (ALDH1), Kruppel-like factor-4 (KLF-4) and sex determining region Y-box-2 (SOX-2) expression (24). Sulphoraphane present in broccoli inhibits tumor spheroid formation and ALDH-1 expression in pancreatic and prostate cancer stem cells (25), inhibits NANOG, ALDH-1, Wnt-3 and Notch expression in triple-negative breast cancer stem cells (26), and benzyl isothiocyanate present in cruciferous vegetables inhibits breast cancer stem cells via upregulation of KLF-4-p21 axis (27). The inhibition of established stem cell markers provides potential mechanistic leads for the stem cell-targeted efficacy of natural products.
In addition to natural phytochemicals, nutritional herbs may represent testable alternatives for therapy resistant breast cancer. Herbal aqueous extracts are extensively used in traditional Chinese medicine for a variety of health issues in women, including cancer (28). Non-fractionated aqueous extracts from Chinese nutritional herbs, simulating patient consumption, exhibit anti-proliferative and pro-apoptotic effects in cellular models for molecular subtypes for clinical breast cancer. In the MCF-7 model for the luminal A subtype, Epimedium grandiflorum extract inhibits cancer growth via altering estrogen metabolism and generating anti-proliferative metabolite 2-hydroxyestrone (29). In the MCF-7AROM model for aromatase-expressing post-menopausal breast cancer, Taheebo-NFD-Marugoto (TNM), an extract from the Tabebuia avellanedae tree, exhibits anti-proliferative effects via inhibition of estrogen regulated genes and pro-apoptotic effects via increase in pro-apoptotic caspase 3/7 activity and upregulation of BAX gene. Additionally, TNM exerts superior inhibitory effects on aromatase activity than clinical aromatase inhibitors (30). In the MDA-MB-231 model for triple-negative breast cancer, Cornus officinalis extract induces anti-proliferative and pro-apoptotic effects via the inhibition of cyclin D1 and pRB, and via the upregulation of caspase-3/7 activity and BAX expression, respectively (31). Collectively, these data provide mechanistic leads for the efficacy of nutritional herbs on models for breast cancer subtypes, and thereby, provide a rationale for investigations on developed stem cell models. It is also notable that the stem cell-specific transcription factors, OCT-4, SOX-2 and NANOG, represent markers for poor survival in HER-2-positive clinical breast cancer (32).
8. Conclusions and future prospects
The data reviewed herein lead to the conclusion that the cellular model for the HER-2-enriched breast cancer subtype in general and drug-resistant stem cell model in particular, provide valuable experimental approaches for identifying natural phytochemicals as testable alternatives for treatment of chemotherapy therapy resistant breast cancer.
Human tissue-derived cellular models represent valuable experimental approaches to reduce preclinical data extrapolation for their clinical translatability. However, to further enhance clinical translatability, future investigations utilizing patient derived ex vivo breast cancer organoid models (33,34) are likely to provide valuable clinically translatable data on stem cell-targeting natural products.
Acknowledgements
The author gratefully acknowledges productive collaboration and active participation of former colleagues in the research program entitled ‘Cellular models for molecular subtypes of clinical breast cancer: Mechanistic approaches for lead compound efficacy’.
Funding
The current research program has been funded in the past by extra-mural grant support from the US National Cancer Institute (NCI) FIRST Award (grant no. CA 44741), NCI Program Project Grant (grant no. PO1 CA 2950, and US Department of Defense Breast Cancer Research Program IDEA Award (grant no. DAMD-17-94-J-4208).
Availability of data and materials
The data sets used and/or analyzed during the current study are available from the author on reasonable request.
Author's contribution
The author NT contributed towards study conception, experimental design and prepared the manuscript.
Ethics approval and consent to participate
Not applicable.
Patient consent for publication
Not applicable.
Competing interests
The author declares that there are no competing interests.
ReferencesSorlieTPerouCMTibshiraniRAasTGeislerSJohnsenHHastieTEisenMBVan de RijnMJeffreySSGene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications98108691087420011155381510.1073/pnas.191367098JohnstonSRDDowsettMAromatase inhibitors for breast cancer: Lessons from the laboratory382183120031466881310.1038/nrc1211BaselgaJSwainSMNovel anti-cancer targets: Revisiting ERBB2 and discovering ERBB3946347520091953610710.1038/nrc2656DeanMFojoTBatesSTumor stem cells and drug resistance52752842005NeveRMChinKFridlyandJYehJBaehnerFLFevrTClarkLBayaniNCoppeJPTongFA collection of breast cancer cell lines for the study of functionally distinct cancer subtypes1051552720061715779110.1016/j.ccr.2006.10.008SubikKLeeJFBaxterLStrezepelTCostelloDCrowleyPXingLHungMCBonfiglioTExpression patterns of ER, PR, HER-2, CK5/6, Ki-67and AR by immune-histochemical analysis in breast cancer cell lines43541201020697531GuptaAMehtaRAlimirahFPengXMurilloGWeihleRMehtaRGEfficacy and mechanism of action Proellex, an anti-progestin in aromatase over-expressing and letrozole resistant T47D breast cancer cells133304220132293988710.1016/j.jsbmb.2012.08.004HoleSPedersenAMHansenSKLundqvistJYdeCWLykkesfeldtAEA new cell culture model for aromatase resistant breast cancer shows sensitivity to fluvestrant treatment and cross resistance between letrozole and exemestane461481149020152562575510.3892/ijo.2015.2850DeyPRathodMDeATargeting stem cells in the realm of drug-resistant breast cancer1111513520193088111010.2147/BCTT.S189224StampferMRBartleyJCInduction of transformation and continuous cell lines from normal human mammary epithelial cell lines after exposure to benzo[a]pyrene. Proc Natl82239423981985385758810.1073/pnas.82.8.2394ZhaiWFBeittenmillerHWangBGouldMNOakleyCEsselmanWJWelchCWIncreased expression of protein tyrosine phosphatases in human breast epithelial cells neoplastically transformed by the neu oncogene532272227819938097963TelangNTargeting drug resistant stem cells in a human epidermal growth factor receptor-2-enriched breast cancer model186912019KatdareMOsborneMTelangNTSoy isoflavone genestein modulates cell cycle progression and induces apoptosis in HER-2 oncogene expressing human breast epithelial cells21809815200212239620TelangNTKatdareMBradlowHLOsborneMPFishmanJInhibition of proliferation and modulation of estradiol metabolism: Novel mechanisms for breast cancer prevention by the phytochemical indole-3-carbinol2162462521997934969310.3181/00379727-216-44174KatdareMJinnoHOsborneMPTelangNTNegative growth regulation of oncogene-transformed human breast epithelial cells by phytochemicals: Role of apoptosis88924725219991066850110.1111/j.1749-6632.1999.tb08742.xTelangNAnti-proliferative and pro-apoptotic effects of rosemary and constituent terpenoids in a model for HER-2-enriched molecular subtype of clinical breast cancer165489549720183021461910.3892/ol.2018.9238SubbaramaiahKColePADannenbergAJRetinoids and carnosol suppress cyclooxygenase-2 transcription by CREB-binding protein/p300 dependent- and-independent mechanisms6225222530200211980644RahmanKMLiYSarkarFHInactivation of Akt and NF-kappaB play important roles during indole-3-carbinol-induced apoptosis in breast cancer cells48849420041520338210.1207/s15327914nc4801_12SchroderLMarahrensPKochGJHeideggerHVilsmeierTPhan-BrehmTHofmannSMahnerSJeschkeURichterDUEffects of green tea, matcha tea and their components epigallocatechin gallate and quercetin on MCF-7 and MDA-MB-231 breast carcinoma cells4138739620193032034810.3892/or.2018.6789Kabala-DzikARzepecka-StojkoAKubinaRIritiMWojtyczkaRDBuszmanEStojkoJFlavonoids, bioactive components of Propolis, exhibit cytotoxic activity and induce cell cycle arrest and apoptosis in human breast cancer cells MDA-MB-231 and MCF-7-a comparative study64110201829981677Al-DaheriYAttoubSRamadanGArafatKBajboujKKaruvantevidaNAbuQamarSEidAIratniRCarnosol induces ROS-mediated beclin1-independent autophagy and apoptosis in triple negative breast cancer9e10963020142529969810.1371/journal.pone.0109630RusnakDWLackeyKAffleckKWoodERAlligoodKJRhodesNKeithBRMurrayDMKnightWBMullinRJGilmerTMThe effects of the novel, reversible epidermal growth factor/ErB2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines18594200112467226NahtaRYuanLXHDuYEstevaFJLapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: Effect on insulin-like growth factor I signaling666767420071730806210.1158/1535-7163.MCT-06-0423NguyenPHGiraudJStaedelCChambonnierLDubusPChevretEBoeufHGauthereauXRousseauBFevreMAll-trans retinoic acid targets gastric cancer stem cells and inhibits patient-derived gastric carcinoma tumor growth355619562820162715761610.1038/onc.2016.87KallifatidisGLabschSRauschVMatternJGaldkichJMoldenhauerDBuchlerMWSalinikovAVHerrISulphoraphane increases drug-mediated cytotoxicity toward cancer stem-like cells of pancreas and prostate1918819520112094070710.1038/mt.2010.216CastroNPRangelMCMerchantASMacKinnonGCuttittaFSalomonDAKimYSSulphoraphane suppresses the growth of triple negative breast cancer stem-like cells in vitro and in vivo1214715820193067915910.1158/1940-6207.CAPR-18-0241KimSHSinghSVRole of Kruppel-like factor-4/p21CIP1 axis in breast cancer stem-like cell inhibition by benzyl isothiocyanate1212513420193072317510.1158/1940-6207.CAPR-18-0393YeIJiaYJiKESandersAJXueKJiJMasonMDJiangWGTraditional Chinese medicine in the prevention and treatment of breast cancer and cancer metastasis101240125020152662265710.3892/ol.2015.3459TelangNTLiGKatdareMSepkovicDWBradlowHLWongGYThe nutritional herb Epimedium grandiflorum inhibits the growth in a model for the Luminal A molecular subtype of breast cancer132477248220172845442310.3892/ol.2017.5720TelangNNairHBWongGYCGrowth inhibitory efficacy and anti-aromatase activity of Tabebuia avellanedae in a model for post-menopausal Luminal A breast cancer1122222920193163267010.3892/br.2019.1244TelangNTNairHBWongGYCGrowth inhibitory efficacy of Cornus officinalis in a cell culture model for triple negative breast cancer175261526620193118674210.3892/ol.2019.10182YangFZhangJYangHOCT4, SOX2 and NANOG positive expression correlates with poor differentiation, advanced disease stages and worse overall survival in HER-2+ breast cancer patients117873788120183046453410.2147/OTT.S173522BrunaARouda OM GreenwoodABatraASCallariMBatraRNPogrebniakKSandovalJCassidyJWTufegdzic-VidakocicAA biobank of breast cancer explants with preserved intra-tumor heterogeneity to screen anti-cancer compounds167260274.e2220162764150410.1016/j.cell.2016.08.041SachsNde LigtJKopperOGogolaEBounovaGWeeberEBalgobindAVWindKGracaninABegthelHA living biobank of breast cancer organids captures disease heterogeneity172373386.e1020182922478010.1016/j.cell.2017.11.010
Hyper-proliferation in the HER-2-enriched 184-B5/HER model.
Cell line
Quantitative end point
184-B5a
184-B5/HERa
P-value
Relative to 184-B5
Population doubling (h)b
34.1±1.7
15.3±4.1
0.04
-55.1%
Saturation density (x105)b
23.7±1.3
38.6±1.7
0.02
+62.9%
G1: S+G2/M (ratio)c
1.8±0.3
0.8±0.2
0.04
-55.6%
Sub-G0 (%)c
18.9±2.6
0.7±0.2
0.01
-96.3%
Anchorage-independent Colony number (per 100 cells)d
Undetected
25.8±4.7
HER-2 (log mean FU)c
0.3±0.1
53.8±2.5
0.005
+178X
p-HER-2 (log mean FU)c
0.2±0.1
46.5±2.2
0.005
+231X
aMean ± SD, n=3 per treatment group.
bDetermined at day 7 post-seeding by the number of viable cells using trypan blue dye exclusion assay.
cDetermined at day 3 post-seeding by PI-positive or FITC-conjugated antibody positive cells using flow cytometry.
dDetermined at day 21 post-seeding by AI colony number using anchorage independent growth assay. Data were analyzed by a two-sample Student's t-test. AI, anchorage independent; HER-2, human epidermal growth factor receptor 2; p-HER-2, phosphorylated HER-2; FU, fluorescence units; PI, propidium iodide; FITC, fluorescence isothiocyanate; X, fold change. Data shown are summarized from a previous study (16).
Anti-proliferative effects of natural phytochemicals in 184-B5/HER cells.
Biomarker
Treatment
Concentration (µM)a
G1: S+G2/Mb
P-value
δ EtOH
p-HER-2c
P-value
δEtOH
EtOH
0.1%
0.7±0.1
-
46.5±3.3
-
I3C
100
1.7±0.2
0.02
+1.4X
34.4±5.6
0.05
-26.0%
EGCG
20
1.5±0.2
0.02
+1.1X
18.7±0.9
0.02
-59.8%
GEN
10
2.9±0.4
0.01
+3.1X
6.9±0.3
0.01
-85.2%
CA
10
1.0±0.1
+42.8%
37.1±1.7
0.05
-20.2%
CSOL
10
1.0±0.1
+42.8%
36.0±1.6
0.05
-22.6%
aIC90, maximum cytostatic.
bDetermined by FACS analysis of PI-positive cells.
cDetermined by immunofluorescence assay using FACS analysis of FITC-conjugated antibody positive cells. Mean ± SD, n=3 per treatment group. Data were analyzed by ANOVA and Dunnett's post-hoc multiple comparison test (α=0.05). FACS, fluorescence assisted cell sorting; PI, propidium iodide; FITC, fluorescence isothiocyanate; EtOH, ethanol (solvent control); p-HER-2, phosphorylated HER-2, I3C, indole-3-carbinol; EGCG, epigallocatechin gallate; GEN, genistein; CA, carnosic acid; CSOL, carnosol, X, fold.
Pro-apoptotic effects of natural phytochemicals in 184-B5/HER cells.
Biomarker
Treatment
Concentration (µM)a
Sub-G0 (%)b
P-value
δEtOH
EtOH
0.1%
0.7±0.2
I3C
100
6.4±1.8
0.02
+8.1X
EGCG
20
8.1±2.3
0.01
+10.6X
GEN
10
12.7±3.6
0.01
+17.1X
CA
10
7.2±2.0
0.02
+9.3X
CSOL
10
10.4±2.9
0.01
+13.8X
aIC90, maximum cytostatic.
bDetermined at day 3 post-seeding by FACS analysis of PI-positive cells. Mean ± SD, n=3 per treatment group. Data analyzed by ANOVA and Dunnett's post-hoc multiple comparison test (α=0.05). FACS, fluorescence-assisted cell sorting, EtOH, ethanol (solvent control); I3C, indole-3-carbinol; EGCG, epigallocatechin gallate; GEN, genistein; CA, carnosic acid; CSOL, carnosol; BCL-2, B-cell lymphoma; BAX, BCL-2-associated X protein, X, fold change.
Modulation of apoptosis associated protein by natural phytochemicals in 184-B5/HER cells.
Biomarker
Treatment
Concentration (µM)a
BCL-2b
P-value
δEtOH
BAXb
P-value
δEtOH
EtOH
0.1%
80.5±5.1
-
25.3±2.7
-
I3C
100
62.1±3.9
0.05
-22.8%
32.6±3.3
0.05
+22.8%
EGCG
20
51.0±3.2
0.05
-36.6%
35.2±3.6
0.04
+39.1%
GEN
10
26.7±1.7
0.01
-66.8%
44.1±4.5
0.01
+74.3%
CA
10
31.5±1.9
0.02
-60.9%
37.5±3.8
0.04
+48.2%
CSOL
10
29.9±1.9
0.02
-62.8%
44.5±4.5
0.01
+75.9%
aIC90, maximum cytostatic.
bDetermined at day 3 post-seeding by FACS analysis of FITC-conjugated antibody-positive cells. Mean ± SD, n=3 per treatment group. Data are presented as log mean FU per 104 fluorescent events, and analyzed by ANOVA and Dunnett's post-hoc multiple comparison test (α=0.05). BCL-2, B-cell lymphoma; BAX, BCL-2 associated X protein; EtOH, ethanol (solvent control); I3C, indole-3-carbinol; EGCG, epigallocatechin gallate; GEN, genistein; CA, carnosic acid; CSOL, carnosol.
Drug-resistant stem cells derived from the lapatinib-resistant (LAP-R) phenotype.
Expression of stem cell markers
Phenotype
Tumor spheroidsa
CD44b
NANOGb
OCT-4b
LAP-S
4.5±1.2
4.0±1.1
2.2±0.6
4.8±1.3
LAP-R
10.3±2.7
16.8±3.6
9.7±2.5
9.1±2.4
χ2
7.88
P-value
0.005
0.01
0.01
0.03
Relative to LAP-S
+1.3X
+3.2X
+3.4X
+1.8X
aNumber of tumor spheroids at day 14 post-seeding.
bDetermined at day 3 post-seeding by flow cytometry of FITC-conjugated antibody-positive cells. Data are presented as log mean FU. Mean ± SD, n=3 per treatment group. Tumor spheroids were analyzed by the χ2 test. CD44, NANOG andOCT-4 were analyzed by a two-sample Student's t-test. CD44, cluster of differentiation 44; NANOG, DNA binding homeobox transcription factor; OCT-4, octamer binding protein-4; LAP-S, lapatinib-sensitive; LAP-R, lapatinib-resistant; FU, fluorescent units; X, fold. Data shown are summarized from a previous study (12).
Modulation of stem cell markers in the lapatinib-resistant (LAP-R) phenotype.
Expression of stem cell markers
Treatment
Concentration
Tumor spheroidsa
CD44b
NANOGb
OCT-4b
DMSO
0.1%
14.8±1.9
20.8±4.4
11.8±3.1
14.2±3.8
CSOL
5 µM
1.9±0.2
2.9±0.6
2.7±0.7
2.9±0.9
χ2
7.74
P-value
0.010
0.010
0.020
0.020
Relative to DMSO
-87.2%
-86.0%
-77.1%
-79.6%
aNumber of tumor spheroids determined at day 14 post-seeding.
bDetermined at day 3 post-seeding by immuno-fluorescence assay of FITC-conjugated antibody-positive cells. Data are presented as log mean FU. Mean ± SD, n=3 per treatment group. Tumor spheroids were analyzed by the χ2 test. CD44, NANOG and OCT-4 were analyzed by a two-sample Student's t-test. CD44, cluster of differentiation 44; NANOG, DNA binding homeobox transcription factor; OCT-4, octamer binding protein-4; DMSO, dimethyl sulfoxide (solvent control); CSOL, carnosol. Data shown are summarized from a previous study (12).